Skip to main
OCUL
OCUL logo

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc has demonstrated significant progress in research and development, with R&D expenses increasing to $52.4 million, reflecting heightened investment in clinical trials that indicate robust growth potential. The strong demand for durable therapies highlighted by management, along with the successful target randomization in the SOL-R trial, suggests a promising market opportunity driven by enhanced patient retention and efficacy of treatments. Additionally, the recent FDA Special Protocol Assessment for AXPAXLI signals regulatory support that could further accelerate the company's pipeline progression and commercial viability in the growing ophthalmic market.

Bears say

Ocular Therapeutix's net revenue for the recent quarter decreased to $14.5 million, down from $15.4 million in the same period last year, indicating potential challenges in revenue growth. The company has sustained substantial losses since its inception, raising concerns about its long-term financial viability. Additionally, Ocular faces significant market competition from existing and emerging therapies, alongside risks associated with delays in clinical development and regulatory approvals, which could adversely affect its market position and profitability.

Ocular Therapeutix (OCUL) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Buy based on their latest research and market trends.

According to 10 analysts, Ocular Therapeutix (OCUL) has a Buy consensus rating as of Dec 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.